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Introduction
Eleucine indica is an annual plant growing to 0.45 m. It is 
in flower from July to August and the seeds ripen from 
August to October. The flowers are monaceous (individual 
flowers are either male or female, but both sexes can be 
found on the same plant) and are polinated by wind. The 
plant prefers light (sandy), medium (loamy) and heavy 
(clay) soils and requires well drained soil. The plant prefers 
acid, neutral and basic (alkaline) soil. It cannot grow in 
the shade. It requires much soil mostly cultivated beds, for 
habitats and possible locations (1). 
This plant is used for the treatment of malaria among the 
Ibibios of Southern Nigeria. The whole plant, especially 
the root, is depurative, diuretic, febrifuge and laxative, and 
hence is used for the treatment of influenza, hypertension, 
oliguria and urinary retention (2). It is also used for 
kidney problems in Trinidad and Tobago (3). The seed 
is sometimes used as a famine food as well as in the 
treatment of liver complaints (4). Two main flavonoids 
have been isolated: schaftoside (6-C-β-glucopyranosyl-
8-C-α-arabinopyranosylapigenin) and vitexin (8- C-β-
glucopyranosylapigenin) based on 1H and 13C NMR 
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Introduction: Eleucine indica is a medicinal plant used by the Ibibios of Nigeria in the treatment 
of malaria but its safety with chronic use has not been determined. This study was to evaluate the 
toxicological effects of the extract in adult albino Wistar rats. 
Methods: The rats of both sexes were randomized into 5 groups of 6 animals per group and orally 
administered with extract (200, 400 and 600 mg/kg) for groups 2–4, respectively. Group 1 received 
distilled water (10 mL/kg) orally and served as negative control while group 5 was administered 
with 100 mg/kg of silymarin orally. Drugs were administered on alternate days for 28 days at 09.00 
am. Toxic manifestations and mortality were monitored daily and weight changes of animals were 
recorded every week. On day 29, after an overnight fast, the animals were weighed, anaesthetized 
with light chloroform. An autopsy was performed during which any macroscopic abnormalities 
were noted. The brain, heart, liver, spleen, kidney and lungs were weighed immediately after 
removal. Samples of these organs were fixed in 10% formalin and kept in that solution for further 
histopathological examination. Data were analysed using one-way analysis of variance (ANOVA) 
followed by Tukey Kramer multiple comparison post-test. 
Results: The results showed that organ weights were not affected but animal weights increased 
significantly (P < 0.01-0.001). Relative organ weights were not affected. The extract caused, at low 
doses, slight inflammation of the liver, spleen, lungs, kidneys and brain. With high dose of the 
extract, the spleen and lungs showed moderate inflammation. The lungs also showed moderate 
interstitial fibrosis. 
Conclusion: Based on these results, the plant has a potential to damage the lungs when used on the 
long term. Its use as herbal remedy should be for short periods at a time.
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spectra and found to have strong anti-inflammatory 
activities (5). Eleucine indica has been reported to have 
phytochemical content of sterol glucoside forms (6) 
and C-glycosyl-flavone possessing anti-inflammatory 
activities (7). E. indica leaves are reported to have good 
bactericidal activity towards methicillin-resistant 
Staphylococcus aureus (MRSA), Bacillus subtilis, 
Pseudomonas aeruginosa and Salmonella choleraesuis, 
antioxidant and non-cytotoxic properties (4). It is native 
in the tropics and subtropical regions (8). It is in flower 
from July to August and the seeds ripen from August 
to October (1). The whole plant, especially the root, is 
depurative, diuretic, febrifuge and laxative. It is used in 
treatment of influenza, and hypertension, oliguria and 
urinary retention (2) and kidney problems in Trinidad 
and Tobago (3). The seed is sometimes used as a famine 
food and in treatment of liver complaints (4). This plant 
is used for the treatment of malaria among the Ibibios of 
Southern Nigeria. It has good bactericidal activity towards 
methicillin-resistant staph aureus (MRSA), B. Subtilis, 
P. aeruginosa and S. choleraesuis, antioxidant and non-
cytotoxic properties (4) and antiplasmodial potentials 
(9). The phytochemical screening indicated the presence 
of alkaloids, tannins, flavonoids, cardiac glycosides, 
terpenes and simple sugar. The median lethal dose (LD50) 
was determined to be 2090 ± 0.01 mg/kg. It has analgesic 
and anti-inflammatory activities (10), antipyretic and 
antioxidant properties (11) and anticonvulsant potentials 
(12). This study was aimed at evaluating the toxicological 
effects of the plant on various organs of the body in order 
to provide information about its safety.
Materials and Methods
Collection and identification of plant sample
Whole plant material of E. indica (leaf, stem and root) was 
collected in 2009 from Uyo, Akwa Ibom State and identified 
and authenticated by Prof. (Mrs.) Margaret Bassey, Dept. 
of Botany and Ecological Studies, University of Uyo, where 
a voucher specimen (UUH 1409) was deposited. Animal 
Ethics Committee, Faculty of Pharmacy, University of 
Uyo, granted approval for animal use.
Animal stock
Adult albino rats from the Animal House of the University 
of Jos were housed in the Animal House, Faculty of 
Pharmacy, University of Uyo and fed with growers pellet 
Feed (Bendel Feeds and Flour mills Ltd, Edo State). Animal 
Ethics Committee, Faculty of Pharmacy, University of 
Uyo, granted approval for animal use.
Histopathology studies 
Using the method of Nongporn et al (13) and Diallo et 
al, (14), adult albino rats (140-200 g) of both sexes were 
weighed and randomized into 5 groups of 6 animals 
per group. Group 1 received 10 mL/kg of distilled water 
orally, and served as control. Groups 2-4 received the 
extract at 200-600 mg/kg orally respectively. Group 5 
animals received 100 mg/kg of silymarin orally. Drugs 
were administered on alternate days for 28 days at 09.00 
am. Toxic manifestations and mortality were monitored 
daily and weight changes of animals were recorded every 
week. On day 29, after an overnight fast, the animals 
were weighed, anaesthetized with light chloroform. An 
autopsy was performed during which any macroscopic 
abnormalities were noted. The brain, heart, liver, spleen, 
kidney and lungs were weighed immediately after removal. 
Samples of these organs were fixed in 10% formalin 
and kept in that solution for further histopathological 
examinations by a Consultant Pathologist at the University 
of Uyo Teaching Hospital. 
On the histopathology analysis, the fixed liver, kidney, 
lungs, brain and spleen and kidney tissues were sectioned 
(5-micron in thickness) and embedded in paraffin. 
Sections were then stained with hematoxylin and eosin. 
This was followed by light microscopic examination of 
multiple tissue sections from each organ in all groups. 
Representative images of the typical histological profile 
were examined. Changes observed were graded as follows: 
(0) showing no changes, and (1) (2) and (3) indicating 
mild, moderate and severe changes, respectively, while 
the grading was determined by percentage as follows: 
Changes less than 30% (50%) showing severe changes. 
Changes less than 30%, mild; 30%-50%, moderate; more 
than 50%; severe (15,16). 
Statistical Analysis
Results were expressed as multiple comparisons of mean 
± standard error of the mean (SEM). Significance was 
determined using one-way analysis of variance (ANOVA) 
followed by Tukey-Kramer multiple comparison post-
test. A probability level of less than 5% was considered 
significant. GraphPad InStat software was used for all data 
analysis.
Results
Effect of extract on body weight of animals
Measurements of the body weight of the animals 
throughout the experimental period showed significant 
differences between the treated and control groups. The 
animals all gained weight as the experiment progressed. 
The increase in weights was reflected in all groups 
treated with extract relative to control. This increase 
was statistically significant (P < 0.01–0.001) as shown in 
Table 1. 
Effect of Eleucine indica extract on relative weight of 
organs
There were no significant changes in the organ weights of 
extract-treated groups compared to control (Table 2).
 
Histopathology 
There was only slight inflammation of the liver (Figure 1), 
spleen (Figure 2), Brain (Figure 3), kidneys (Figure 4) and 
lungs (Figure 5), with low doses of the extract. However, 
with high dose of the extract, the spleen and lungs showed 
moderate inflammation. The lungs also showed mild 
The toxic assessment of Eleucine indica 
Journal of Herbmed Pharmacology, Volume 6, Number 2, April 2017http://www.herbmedpharmacol.com 51
epithelial degeneration, cellular proliferation and moderate 
interstitial fibrosis. The heart (Figure 6) was not affected 
in all groups. All the animals treated with the extract had 
normal cellular architecture, nucleocytoplasmic ratio and 
nuclear structure. No necrosis, malignancy, pigment or 
inclusion bodies were observed.
Discussion
Herbal medicines are generally seen by people as being 
natural, healthy and without side effects. The chemicals in 
medicinal plants may be natural to the plant, but foreign 
to the human body and may be harmful resulting in issues 
of safety and efficacy (17). 
Table 1. Effect of subchronic toxicity of Eleucine indica on body weights of rats
Dose (mg/kg)
 Week
0 1 2 3 4
Control 168.67 ± 0.14 184.00 ± 0.10d 192.17 ± 0.13 d 196.17 ± 0.14 d 199.00 ± 0.50 d
Extract  200 160.00 ± 0.22c 177.83 ± 0.21c d 189.33 ± 0.05 c d 194.83 ± 2.07 d 197.33 ± 0.06 d
 Extract 400 164.83 ± 0.35c 180.00 ± 0.20 c d 193.17 ± 0.13 d 199.50 ± 0.22 d 202.17 ± 1.55 d
 Extract 600 163.83 ± 0.11c 180.17 ± 0.11 c d 188.33 ± 0.15 c d 190.50 ± 0.30 b d 196.33 ± 1.05 d
Silymarin 100 160.67 ± 0.31c 180.00 ± 0.04 c d 193.00 ± 0.59 d 200.33 ± 0.07a d 213.33 ± 0.30 c d
Values represent Mean ± SEM. Significance relative to control a P < 0.05; b P < 0.01, c P < 0.001; d P < 0.001 (n = 6).
Table 2. Relative organ weight of rats in subchronic administration of Eleucine indica extract
Dose (mg/kg) Liver Kidney Spleen Lung Heart Brain
Control 2.67 ± 0.37 0.27 ± 0.39 0.37 ± 0.03 0.56 ± 0.15 0.34 ± 0.07 0.88 ± 0.03
 Extract 200 2.63 ± 0.37
 
0.29 ± 0.03 0.34 ± 0.05 0.63 ± 0.14 0.34 ± 0.05 0.87 ± 0.05
 Extract 400 2.51 ± 0.12 0.25 ± 0.05 0.32 ± 0.05 0.64 ± 0.09 0.32 ± 0.04 0.83 ± 0.03
Extract 600 2.57 ± 0.39 0.27 ± 0.03 0.31 ± 0.05 0.65 ± 0.08 0.32 ± 0.01 0.85 ± 0.05
Silymarin 100 2.58 ± 0.26 0.29 ± 0.03 0.34 ± 0.02 0.70 ± 0.14 0.33 ± 0.07 0.82 ± 0.05
Values represent Mean + SEM;  n=6.
Figure 1. Histopathologic sections of liver (A) Control: Normal; (B) 
Extract 200 mg/kg x400: Slightly inflamed; (C) Extract 400 mg/kg 
x400: Slightly inflamed; (D) Extract 600 mg/kg x400: Slightly inflamed; 
(E) Silymarin 100 mg/kg x400: Slightly inflamed.
CV, central vein; VC, vascular congestion; H, hepatocyte; SL, 
sinusoidal layer; HA, hepatic artery; HV, hepatic vein; BD, bile-duct; N, 
nucleus; EL, epithelial lining; L, lumen; PT, portal triad; I, inflammation.
Figure 2. Histopathologic sections of spleen (A) Control: Normal; 
(B) Extract 200 mg/kg x400: Slightly inflamed; (C) Extract 400 mg/
kg x400: Slightly inflamed; (D) Extract 600 mg/kg x400: Moderately 
inflamed; (E) Silymarin 100 mg/kg x400: Moderately inflamed.
MC, medullary cortex; MS, medullary sinus; LN, lymph node; PMC, 
polymorphomer cell; N, nucleus; TBV, trabecular blood vessel; WP, 
white pulp; RP, Red-Pulp; GC, germinal centre; C,  cortex.
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Figure 3: Histopathologic sections of Spleen (A) Control: Normal; (B) - Extract 200 mg/kg x 400: Slightly inflammed); (C) - 
Extract 400 mg/kg x400: Slightly inflamed; (D) - Extract 600 mg/kg x400: oderately inflammed; (E) - Silymarin 100 mg/kg x 
400: Moderately inflammed 
 
MC – Medullary Cortex, MS – Medullary Sinus, LN – Lymph Node, PMC – Polymorphomer Cell, N – Nucleus, TBV – 
Trabecular Blood Vessel, WP – White Pulp, RP – Red-Pulp, GC – Germinal centre, C -  Cortex 
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Drugs and their metabolites can interact with a diverse 
array of receptors to mediate adverse effects in vivo. 
Sometimes the parent, unmetabolized drug causes 
toxicity, but often a metabolite of the drug reacts with 
proteins, DNA, and oxidative defense molecules (such as 
glutathione) to cause cellular damage and other adverse 
reactions. The response to injury after cellular damage is 
largely determined by the regenerative capacity of the target 
organ. In organs that are capable of regeneration, such as 
the liver, repeated insults may be followed by regeneration 
(18). Over time, however, cellular injury can lead to 
excessive deposition of collagen and extracellular matrix 
proteins, causing fibrosis. Organ systems with limited or 
no regenerative function, such as cardiac and neuronal 
tissue, lose function as tissue is destroyed. Chronic toxicity 
in the lungs can be manifested as both loss of function 
and fibrosis. Liver and kidney are the major organs 
involved in toxicity (18). The kidney is also susceptible 
to toxic insult because it concentrates many xenobiotics 
for excretion. There was only slight inflammation of the 
liver, spleen, lungs, kidneys and brain with low doses of 
the extract. However, with high dose of the extract, the 
spleen and lungs showed moderate inflammation. The 
lungs also showed mild epithelial degeneration, cellular 
proliferation and moderate interstitial fibrosis. The heart 
was not affected in all groups. All the animals treated 
with the extract had normal cellular architecture, nucleo-
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Figure 4: Histopathologic Sections of brain (A) Control x 100: Normal; (B) - Extract 200 mg/kg x 100: Slightly inflammed; (C) 
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Figure 3. Histopathologic sections of brain (A) Control x100: Normal; 
(B)  Extract 200 mg/kg x100: Slightly inflamed; (C) Extract 400 mg/
kg 1 : Slightly infl d; (D) Extract 6  g/kg x100: Nor al 
architecture; (E) Silymarin 100 mg/kg x100: Slightly inflamed.
ML, molecular layer; GL, granular layer; PC, purkinje cell; BC, basket 
cells; CC, cerebellar cortex; CF, cerebrospinal folia; IS, interfolia  sulci; 
GM, gray matter; WM, white matter; PM, pia matter.
Figure 4. Histopathologic sections of kidneys (A) Control: Normal; 
(B) Extract 200 mg/kg x400: Slightly inflamed; (C) Extract 400 mg/kg 
x400: Slightly inflamed; (D) Extract 600 mg/kg x400: Slightly inflamed; 
(E) Silymarin 100 mg/kg x400: Normal.
DCT, distal convulated tubules; PCT, poximal convulated tubules; G, 
glomerulus; RC, renal corpuscle; GI, glomerula inflammation; CD, 
collecting duct; LH, loop of henle; VD, vascular degeneration; SEL, 
squamous epithelial lining; ELD, epithelial lining degeneration; N, 
nucleus.
Figure 5. Histopathologic sections of lungs (A) Control: Normal; (B) 
Extract 200 mg/kg x100: Slight interstitial fibrosis and inflammation; 
(C) Extract 400 mg/kg x100: Moderate interstitial fibrosis and 
inflammation; (D) Extract 600 mg/kg x400: Moderate interstitial fibrosis 
and inflammation (E) Silymarin 100 mg/kg x100: Slight interstitial 
fibrosis and inflammation   
B, bronchus; RB, respiratory bronchiole; AS, air sac; AD, alveolar 
duct; A, alveolus; ELD, epithelial lining degeneration; VD, vascular 
degeneration; IF, interstial fibrosis; CD, cellular degeneration; CT, 
connective tissue.
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Figure 6: Histopathologic sections of Lungs (A) Control: Normal; (B) - Extract 200 mg/kg x 100: Slight interstitial fibrosis and 
inflammation; (C) -  Extract 400 mg/kg x100: Moderate interstitial fibrosis and inflammation; (D) - Extract 600 mg/kg x400: 
Moderate interstitial fibrosis and inflammation (E) - Silymarin 100 mg/kg x 100: Slight interstitial fibrosis and inflammation    
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Figure 5: Histopathologic sections of Kidneys (A) Control: Normal ; (B) - Extract 200 mg/kg x 400: Slightly inflammed; (C) -  
Extract 400 mg/kg x400: Slightly inflammed ; (D) - Extract 600 mg/kg x400: Slightly inflammed; (E) - Silymarin 100 mg/kg x 
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cytoplasmic ratio and nuclear structure. No necrosis, 
malignancy, pigment or inclusion bodies were observed. 
The extract caused significant increase in the body weight 
of the animals compared to control. The increase in body 
weight is probably due to protein anabolic effect (19,20). 
Another possible reason of increase in body weight may be 
the presence of tannins and phenolics in the extract (4,21). 
It may also be attributed to appetite stimulatory effect of 
the extract. The regulation of appetite is a complex process 
involving the gastrointestinal tract, many hormones, aging 
and both the central and autonomic nervous systems (22). 
This stimulatory effect may have resulted in increased 
food and water intake by the extract-treated animals (23). 
The extract did not cause significant changes in organs of 
localization such as kidney, liver, spleen, brain and heart 
which depicted its low toxicity. The liver and kidney 
which are the most sensitive organs to toxic factors were 
apparently normal and showed no signs of dysfunction 
(13). However, the extract caused mild- to- moderate 
interstitial fibrosis in the lungs. This suggests that the 
extract should be avoided in patients whose respiratory 
function is already compromised. The toxicological data 
obtained from this study are of significance in relation 
to the consumption of this extract for health benefits 
especially in the treatment of malaria. Further studies to 
evaluate the chronic toxicity of this whole-plant extract, is 
needed to determine its long-term safety. 
Figure 6. Histopathologic sections of hearts (A) Control: Normal; 
(B) Extract 200 mg/kg x100: Not affected (Normal architecture); (C) 
Extract 400 mg/kg x100 Heart: Not affected (Normal architecture); (D) 
Extract 600 mg/kg x100: (Normal architecture); (E) Silymarin 100 mg/
kg x100: Not affected (Normal architecture) . 
PF, purkinje fibres; ICS, intercelular spaces; CM, cardiac muscle; Mc, 
myocite; M, myocardium; CMF, cardiac muscle fibre; BV, blood vessel; 
CT, connective tissue; MF, muscle.
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Conclusion
The extract caused, at low doses, slight inflammation of 
the liver, spleen, lungs, kidneys and brain. With high dose 
of the extract, the spleen and lungs showed moderate 
inflammation. The lungs also showed moderate interstitial 
fibrosis. The relative organ weights in extract-treated 
animals were not significantly different from control. It 
is advisable that those using this plant as herbal remedy 
should use it for short periods at a time because of its 
effect on the lungs.
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